Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Anya Lublinsky"'
Autor:
Xingyue He, Mark G. Qian, Matthew O. Duffey, Larry Cohen, Michael D. Sintchak, Mi-Sook Kim, Jessica Riceberg, Vaishali Shindi, Kelly Connolly, Jianping Guo, Agatha Zawadzka, Rachel E. Gershman, Teresa A. Soucy, Neil Bence, Zhigen Hu, Xiaofeng Yang, Shumet A. Hailu, Nina Molchinova, Nanda Gulavita, Ji Zhang, Hirotake Mizutani, Keli Song, A D Patil, Scott Freeze, Jessica Grieves, Dylan Bradley England, Roushan Afroze, James J. Minissale, Anya Lublinsky, Mitsuhiro Ito, David Lok, Scott Weston Lane, William D. Mallender, Stephen Grossman, Kara Hoar, Nitya Durvasula, Bei-Ching Chuang, Yongbo Hu, Steven P. Langston, Sai M. Pulukuri, Miho Mizutani, Ryan Chau, Nancy Bump, Katherine M. Galvin, Christopher F. Claiborne, Paul D. Greenspan, He Xu, Gaulin Jeffrey L, Melissa Gallery, Douglas Bowman, Yana Wang, Koji Ono, Mcintyre Charles
Publikováno v:
Journal of medicinal chemistry. 64(5)
SUMOylation is a reversible post-translational modification that regulates protein function through covalent attachment of small ubiquitin-like modifier (SUMO) proteins. The process of SUMOylating proteins involves an enzymatic cascade, the first ste
Autor:
Richard Labotka, Yuhong Zhang, Divya Manoharan, Ajeeta B Dash, Erin Willert, Robert F. Cornell, Jack P. Higgins, Roger J. Waltzman, Michael J. Hanley, Jianchang Lin, Alexander Vorog, Ola Landgren, Morgan Leichter, Sikander Ailawadhi, Anya Lublinsky, Sean Ottinger, Shaji Kumar, John Newcomb
Publikováno v:
Blood. 134:1867-1867
Background CD38 is highly expressed on MM cells, hence anti-CD38 agents are of interest as a therapeutic approach in MM. The anti-CD38 monoclonal antibody, dara, as mono- or combination therapy, has substantially improved efficacy outcomes in RRMM, i
Autor:
Jack P. Higgins, Sanjay Patel, Garrett L. Robinson, Nibedita Chattopadhyay, Carole E. Harbison, Pu Shi, Jensing Liu, Dan Tavares, Anya Lublinsky, Haiqing Wang, Erin Willert, Sakeena Syed, John Newcomb, Janice Lee, Laura E. Packer, Yuhong Zhang
Publikováno v:
Cancer Research. 79:2384-2384
Advances in the treatment of multiple myeloma have been driven by the development of new modalities, including proteasome inhibitors, immunomodulatory agents and monoclonal antibodies. TAK-169 is an engineered toxin body (ETB) comprising a proprietar
Autor:
John Newcomb, James M. Gavin, Nancy J. Bump, Stephen Tirrell, Lawrence R. Dick, Saurabh Menon, Jessica Huck, Petter Veiby, Benjamin S. Amidon, Yu Yang, Marc L. Hyer, Paul D. Greenspan, Fleming Paul E, Teresa A. Soucy, Jim Brownell, Michael Sintchak, Josh Powe, Steve Langston, Mark Manfredi, Judy Shi, Jeff Ciavarri, Darshan S. Sappal, Frank Bruzzese, Mike Kuranda, Katherine Galvin, Michael Milhollen, Ping Li, Neil F. Bence, Jing Tao Wu, Claudia Rabino, Chris Claiborne, Tary Traore, Jennifer Duffy, Jessica Riceberg, Robert J. Griffin, Kara Hoar, Anya Lublinsky, Bradley Stringer, Sai M Pulukuri
Publikováno v:
Nature medicine. 24(2)
The ubiquitin-proteasome system (UPS) comprises a network of enzymes that is responsible for maintaining cellular protein homeostasis. The therapeutic potential of this pathway has been validated by the clinical successes of a number of UPS modulator